Approval · Notice of Compliance 14339 · 2013
HEXABRIX 200: Notice of Compliance 14339
Issued May 6, 2013
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 14339
- Date
- May 6, 2013
- Company
- GuerbetRoissy Cdg Cedex, Val-D'Oise, France
- Product type
- Nonprescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Manufacturer name change
- Therapeutic class
- Ionic, low osmolallity , water soluble radiopaque contrast medium for intravascular use
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| HEXABRIX 200 | 00788805 | Cancelled Post Market |
| HEXABRIX 320 | 00603740 | Cancelled Post Market |
Medicinal ingredients
- IOXAGLATE MEGLUMINE 246 MG per ML
- IOXAGLATE SODIUM 123 MG per ML
- IOXAGLATE MEGLUMINE 393 MG per ML
- IOXAGLATE SODIUM 196 MG per ML